Global Bioengineered Protein Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Bioengineered Protein Drugs Market is presumed to reach the market size of nearly USD 645.59 Billion by 2032 from USD 346.76 Billion in 2023 with a CAGR of 7.15% under the study period 2024-2032.

Bioengineered protein drugs are pharmaceutical products created using biotechnology techniques to produce proteins that mimic those naturally occurring in the body. These drugs target specific biological pathways or molecules involved in disease processes, offering targeted therapies for various medical conditions such as autoimmune disorders, cancer, and genetic diseases. These drugs are produced using recombinant DNA technology, where genes encoding the desired protein are inserted into host cells such as yeast, bacteria, or mammalian cells, which act as miniature protein factories. These drugs have revolutionized medical treatment by providing highly effective and often more targeted therapies with fewer side effects compared to traditional drugs.

MARKET DYNAMICS

The proliferating prevalence of chronic diseases such as cancer, autoimmune disorders, and metabolic diseases is driving the demand for targeted and biologically-based therapies that offer enhanced efficacy & reduced side effects than traditional pharmaceuticals. Bioengineered protein drugs, including monoclonal antibodies, cytokines, and growth factors, provide precise targeting and modulation of disease pathways, leading to better patient outcomes and quality of life. Additionally, advancements in biotechnology and genetic engineering techniques allow the development of novel protein therapeutics with enhanced potency, specificity, and stability, expanding the therapeutic options available to patients and healthcare providers. Moreover, the growing investment in research and development by biopharmaceutical companies and academic institutions is driving innovation in bioengineered protein drug discovery and development, leading to the discovery of novel drug targets and therapeutic modalities. Furthermore, the increasing adoption of personalized medicine approaches and biomarker-driven treatment strategies drives demand for bioengineered protein drugs tailored to individual patient characteristics and disease profiles, improving treatment outcomes and reducing healthcare costs. The growing acceptance of bioengineered protein drugs by regulatory agencies and payers, including the FDA and CMS, facilitates market access and reimbursement for these innovative therapies, further driving market growth and adoption. However, advancements in biopharmaceuticals and alternative treatment modalities may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Bioengineered Protein Drugs. The growth and trends of Bioengineered Protein Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Bioengineered Protein Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others)
Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase))
Vaccines

By Disease Condition

Cancer
Diabetes
Autoimmune Disorder
Infectious Disease
Hematopoiesis
CVD
Neurodegenerative
Others

By End-user

Pharma and Biotech Companies
CROs
Research Institutes

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Bioengineered Protein Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Bioengineered Protein Drugs market include Abbott, Amgen Inc., Bayer AG, Biocon, Dr. Reddy'S Laboratories, Lilly, F. Hoffmann - La Roche Ltd., Fresenius Kabi AG, GSK, Janssen Global Services, Merck & Co. Inc., Novartis AG, Panacea Biotec, ProBioGen AG, Reliance Life Science, Sanofi. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114477

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. BIOENGINEERED PROTEIN DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Disease Condition
- 3.7.3 Market Attractiveness Analysis By End-user
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Monoclonal Antibodies (Humira, Rituxan, Avastin, Herceptin, Remicade, Lucentis, Enbrel, Synazis, Others) Historic and Forecast Sales By Regions
5.5. Therapeutic Proteins (Hormones, Cytokines(Neupogen, Neulasta, Interferon Alpha, Erythropoietin Alpha, Interleukin, Others) Blood Factor, Enzyme Therapy (Systemic Enzyme Therapy, Digestive Enzyme Therapy), Thrombolytics (tPA Streptokinase, Urokinase)) Historic and Forecast Sales By Regions
5.6. Vaccines Historic and Forecast Sales By Regions

6. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY DISEASE CONDITION

6.1. Overview By Disease Condition
6.2. Historical and Forecast Data
6.3. Analysis By Disease Condition
6.4. Cancer Historic and Forecast Sales By Regions
6.5. Diabetes Historic and Forecast Sales By Regions
6.6. Autoimmune Disorder Historic and Forecast Sales By Regions
6.7. Infectious Disease Historic and Forecast Sales By Regions
6.8. Hematopoiesis Historic and Forecast Sales By Regions
6.9. CVD Historic and Forecast Sales By Regions
6.10. Neurodegenerative Historic and Forecast Sales By Regions
6.11. Others Historic and Forecast Sales By Regions

7. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY END-USER

7.1. Overview By End-user
7.2. Historical and Forecast Data
7.3. Analysis By End-user
7.4. Pharma and Biotech Companies Historic and Forecast Sales By Regions
7.5. CROs Historic and Forecast Sales By Regions
7.6. Research Institutes Historic and Forecast Sales By Regions

8. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE BIOENGINEERED PROTEIN DRUGS COMPANIES

9.1. Bioengineered Protein Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF BIOENGINEERED PROTEIN DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Abbott
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Amgen Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Bayer AG
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Biocon
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Dr. Reddy'S Laboratories
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Lilly
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. F. Hoffmann - La Roche Ltd.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Fresenius Kabi AG
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. GSK
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Janssen Global Services
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Merck & Co. Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. Novartis AG
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments
10.15. Panacea Biotec
- 10.15.1 Company Overview
- 10.15.2 Company Revenue
- 10.15.3 Products
- 10.15.4 Recent Developments
10.16. ProBioGen AG
- 10.16.1 Company Overview
- 10.16.2 Company Revenue
- 10.16.3 Products
- 10.16.4 Recent Developments
10.17. Reliance Life Science
- 10.17.1 Company Overview
- 10.17.2 Company Revenue
- 10.17.3 Products
- 10.17.4 Recent Developments
10.18. Sanofi
- 10.18.1 Company Overview
- 10.18.2 Company Revenue
- 10.18.3 Products
- 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies